Welcome to the 4th International Nanotechnology Conference & Expo in Philadelphia, USA!
The main aim of this conference is to gather world class experts both from academia and industry under a common platform to effectively discuss advancements in the field of nanotechnology. And, in case you missed it and as you can see below, a lot has been happening in nanotechnology over the past several years!
Nanotechnology is a highly interdisciplinary field bringing together many aspects of life and science involving physics, chemistry, biology, material science and the full range of engineering disciplines. Over the recent decades, nanotechnology has captured wide attention across various areas such as energy, the environment, cosmetics, medicine and healthcare, drugs, information technology, and soforth.
Particularly, the emergence of nanotechnology has set high expectations for the future of medicine and biological science with some even speculating it could lead to less hospitals and more implantable sensors.
Although most FDA regulations were written before the advent of nanotechnology, the FDA has approved many products which use nanomaterials (usually referred to the manipulation of materials at extremely small sizes, usually 1-100 nm to create new and unique materials and products) with enormous potential to change society.
Here are some additional facts about nanotechnology that you may not know:
* According to BCC Research, the global nanotechnology market should reach $90.5 billion by 2021, from $39.2 billion in 2016, at a compound annual growth rate (CAGR) of 18.2%. The nanomaterials market (which includes nanomedicines) should reach $77.3 billion by 2021 from $32.5 billion in 2016 at a CAGR of 18.9%.
* In 2016, US $500 million was invested by the US Department of Health and Human Services and US $316 million by venture capital (VC) in nanomedicine, and The Freedonia Group estimated that the market for medical devices containing nanomaterials is US $2.4–24 billion annually.
* A 2016 pharmaceutical review reported 51 FDA-approved nanomedicines and 77 products in clinical trials, with ~40% of trials listed in clinicaltrials.gov started in 2014 or 2015.
* The number of clinical trials involving nano-sized components has increased more than 3-fold from 2010 to 2013.
So, I hope to see you at this unique conference where we will discuss these issues and the future, this exciting field holds!
Thomas J. Webster
Arthur W. Zafiropoulo Chair & Professor
Past President of U.S. Society For Biomaterials